


PHARMACEUTICAL 2022

Astria Therapeutics Inc. Rank 459 of 475









Astria Therapeutics Inc. Rank 459 of 475

The relative strengths and weaknesses of Astria Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Astria Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 239% points. The greatest weakness of Astria Therapeutics Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 932% points.

The company's Economic Capital Ratio, given in the ranking table, is -990%, being 713% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	127,075
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,203
Liabilities, Non-Current	0
Other Assets	439
Other Compr. Net Income	0
Other Expenses	164,617
Other Liabilities	0
Other Net Income	64
Property and Equipment	0
Research and Development	15,552
Revenues	0
Selling, General and Administrative Expense	14,807

Output Variable	Value in 1000 USD
Assets	127,514
Liabilities	5,203
Expenses	194,976
Stockholders Equity	122,311
Net Income	-194,912
Comprehensive Net Income	-194,912
Economic Capital Ratio	-990%

